Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
61 hedge funds and large institutions have $128M invested in Immune Design Corp. in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 27 increasing their positions, 11 reducing their positions, and 8 closing their positions.
145% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 11
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
46% more capital invested
Capital invested by funds: $87.6M → $128M (+$40.7M)
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
5% more funds holding
Funds holding: 58 → 61 (+3)
0.9% more ownership
Funds ownership: 50.66% → 51.56% (+0.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$2.18M |
| 2 |
JP Morgan Chase
New York
|
+$2.02M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.18M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$1.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$8.39M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.13M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$377K |
| 4 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$340K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$237K |
IMDZ Hedge Fund Activity: Q2 2017 in Review
61 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q2 2017, worth a combined $128M — up 46% from $87.6M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new IMDZ positions and 8 closed out — a net gain of 3 holders — while 27 added to existing stakes and 11 trimmed.
The largest buyer was Bain Capital Public Equity Management, adding an estimated $2.18M. The largest seller was BVF Inc, exiting entirely with an estimated $8.39M sold.
- 61 institutional investors held Immune Design Corp. (IMDZ) as of Q2 2017, up from 58 in Q1 2017.
- Funds reported $128M of Immune Design Corp. stock for Q2 2017, up 46% quarter-over-quarter.
- 11 funds opened new Immune Design Corp. positions in Q2 2017 and 8 closed out, a net change of +3 holders.
- The largest Immune Design Corp. buyer in Q2 2017 was Bain Capital Public Equity Management, an estimated $2.18M added.
- The largest Immune Design Corp. seller in Q2 2017 was BVF Inc, an estimated $8.39M sold.
Based on aggregated 13F filings for Q2 2017.